EUVIMEDEUVIMED entdecken
Open Access · CC0

Polymorphisms in Pfkelch13 domains before and after the introduction of artemisinin-based combination therapy in Southwest Nigeria

Abiodun Amusan iD, Olugbenga Akinola, Kazeem Akano, María Hernández-Castañeda, Jenna K Dick iD, Akintunde Sowunmi, Geoffrey Hart, Grace Gbotosho

PLOS ONE · 31.03.2025 · 20 (3) · e0316479

DOI: 10.1371/journal.pone.0316479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 31.03.2025. Verfasst von Abiodun Amusan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria. Hauptthemen laut MEDLINE: Artemisinins, Plasmodium falciparum, Malaria, Falciparum, Antimalarials. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Bassir-Thomas Biomedical Foundation, Bureau of Educational and Cultural Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emergence of artemisinin resistance in East Africa has greatly necessitated surveillance of artemisinin resistance in other African countries with great malaria burden. Specific mutations within the β-propeller and BTB/Poz domains of Pf kelch13 gene are validated markers of artemisinin resistance. Sparse information exists on mutations outside these domains that may also contribute to artemisinin resistance. This study evaluated the occurrence and frequency of mutations in all domains of Pf kelch13 gene, and their impact on treatment outcome in Ibadan pre- and post-adoption of Artemisinin-based Combination Therapies (ACTs) in Nigeria. Dry blood spots prepared from blood samples obtained from P. falciparum -infected patients during retrospective (2000–2005) and prospective (2021) studies were analysed. Treatment outcomes with dihydroartemisinin-piperaquine were evaluated in a cohort of patients from the prospective study during a 42-day follow-up. Nested amplifications of Pf kelch13 gene fragments were done and subjected to Sanger dideoxy sequencing. Mutations were identified by sequence alignment and correlated with treatment outcome parameters including parasite clearance time (PCT) and day 2 parasite reduction ratio (PRRD 2 ) among others. Mean PCT was 2.1 ± 0.6 days (95%CI: 1.97–2.24) while PRRD 2 was 4815 with 100% adequate clinical and parasitological response. Altogether, 64 (11 retrospective/53 prospective) samples were successfully sequenced. None of the β-propeller domain mutations validated as artemisinin resistance markers were found within the analysed samples. However, four distinct mutations, K189T (64.2%), K189N (1.9%), R255K (3.8%), and N217H (1.9%) were identified within the N-terminal domain of the prospective samples while the K189T mutation was identified in a retrospective sample obtained in 2003. The K189T and R255K mutations correlated significantly with longer parasite clearance time in treated patients (P < 0.002). There was no evidence of validated molecular marker of artemisinin resistance within the ß-propeller domain of Pf kelch13. However, frequency of K189T mutation and its significant correlation with longer PCT may suggest possibilities of geographical variations in genetic drivers of artemisinin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtemisininsPlasmodium falciparumMalaria, FalciparumAntimalarialsProtozoan ProteinsPolymorphism, GeneticHumansNigeriaMaleFemaleDrug ResistanceDrug Therapy, CombinationRetrospective StudiesMutationProspective StudiesChild, PreschoolChildTreatment OutcomeQuinolinesPiperazines

Substanzen

ArtemisininsAntimalarialsProtozoan ProteinsartemisininartenimolpiperaquineQuinolinesPiperazines

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
  • Malaria Research Laboratories, Institute for Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
  • Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria.
  • Department of Biological Sciences and African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
  • Department of Medicine, Center for Immunology, University of Minnesota, Minneapolis, Minnesota, United States of America.

ORCID-Profile: Abiodun Amusan, Jenna K Dick

Förderung

  • Bassir-Thomas Biomedical Foundation
  • Bureau of Educational and Cultural Affairs

Zitieren

APA

Amusan, A., Akinola, O., Akano, K., Hernández-Castañeda, M., Dick, J. K., Sowunmi, A., Hart, G., & Gbotosho, G. (2025). Polymorphisms in Pfkelch13 domains before and after the introduction of artemisinin-based combination therapy in Southwest Nigeria. PLOS ONE, 20(3), e0316479. https://doi.org/10.1371/journal.pone.0316479

Vancouver

Amusan A, Akinola O, Akano K, Hernández-Castañeda M, Dick JK, Sowunmi A, et al. Polymorphisms in Pfkelch13 domains before and after the introduction of artemisinin-based combination therapy in Southwest Nigeria. PLOS ONE. 2025;20(3):e0316479. doi:10.1371/journal.pone.0316479

BibTeX
@article{Amusan2025,
  author = {Amusan, Abiodun and Akinola, Olugbenga and Akano, Kazeem and Hernández-Castañeda, María and Dick, Jenna K and Sowunmi, Akintunde and Hart, Geoffrey and Gbotosho, Grace},
  title = {Polymorphisms in Pfkelch13 domains before and after the introduction of artemisinin-based combination therapy in Southwest Nigeria},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {e0316479},
  doi = {10.1371/journal.pone.0316479}
}
Kostenlos starten →